Welcome To The Critical Outcome Technologies Inc HUB On AGORACOM

Our disease Targets > Small cell lung cancer, Multiple sclerosis, HIV Integrase, Colorectal cancer & Adult acute leukemia

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Message: Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers

This company seems to be dying on the vine.  Great Partnerships, impressive Scientific Advisory Board, Small but what seems to be capable management, although what the recent changes infer is anyones guess.

Re: Orphan Drug Status, Under Orphan Drug Designations and Approvals, FDA.

could find nothing for COTI-2. 

Good story but lack of cash could be the bogeyman. This board is also pretty well dead. Anyone got thoughts? 

Share
New Message
Please login to post a reply